AEON Biopharma, Inc. (AEON AMEX) stock market data APIs
$0.2463
0.03(12.2%)
as of October 12, 2026
Try our APIs with
free plan!
AEON Biopharma, Inc. Financial Data Overview
Price chart is built with
Anychart
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Prev. Close
0.2463
Open
0.2716
High
0.2843
Low
0.2442
52 wk Range
0.177-1.45
Market Cap
13 768 K
Shares Outstanding
49 883 K
EPS
-0.02
Beta
0.686
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AEON Biopharma, Inc. data using free add-ons & libraries
Get AEON Biopharma, Inc. Fundamental Data
AEON Biopharma, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -19 818 000
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AEON Biopharma, Inc. News
New
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
AEON Biopharma Inc ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a bios...
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to ...
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...
Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight
The cervical dystonia market is expected to increase due to an increase in disease prevalence during the forecast period. Additionally, the expected launch of emerging therapies such as ABP-450 (prabo...
Get AEON Biopharma, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.